Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

J Monk

Showing results (121-130 of 738) with videos related to

Pageof 74
Sort By:
Gynecologic Oncology|August 20, 2020
Real world experience of poly (ADP-ribose) polymerase inhibitor use in a community oncology practiceCortney M Eakin, Agnes Ewongwo, Lee Pendleton, et al.
Critical Reviews in Oncology/Hematology|November 10, 2012
Antiangiogenic agents as a maintenance strategy for advanced epithelial ovarian cancerBradley J Monk, Heather Dalton, John H Farley, et al.
Gynecologic Oncology|June 23, 2006
Salvage bevacizumab (rhuMAB VEGF)-based therapy after multiple prior cytotoxic regimens in advanced refractory epithelial ovarian cancerBradley J Monk, Ernest Han, Carol A Josephs-Cowan, et al.
International Journal of Gynecological Cancer : Official Journal of the International Gynecological Cancer Society|September 14, 2004
Evaluation of tamoxifen in persistent or recurrent nonsquamous cell carcinoma of the cervix: a Gynecologic Oncology Group studyL R Bigler, J Tate Thigpen, J A Blessing, et al.
Plastic and Reconstructive Surgery|January 1, 1995
Breast reduction for symptomatic macromastia: can objective predictors for operative success be identified?A P Miller, J B Zacher, R B Berggren, et al.
Journal of Lower Genital Tract Disease|April 7, 2007
Is atypical squamous cells that cannot exclude high-grade squamous intraepithelial lesion clinically significant?Michael T McHale, Jessica Souther, John C Elkas, et al.
International Journal of Gynecological Cancer : Official Journal of the International Gynecological Cancer Society|July 13, 2007
Bevacizumab demonstrates activity in advanced refractory fallopian tube carcinomaN Arora, D Tewari, C Cowan, et al.
Clinical Oncology (Royal College of Radiologists (Great Britain))|August 3, 2010
First quinquennial review of intensity-modulated radiotherapy at St Bartholomew's Hospital, LondonD Smith, N MacDougall, J Monk, et al.
Gynecologic Oncology|September 30, 1999
Does human papillomavirus have a role in cancers of the uterine corpus?W R Brewster, B J Monk, R A Burger, et al.
Cancer Biology & Therapy|January 11, 2021
Ovarian cancer: new strategies and emerging targets for the treatment of patients with advanced diseaseRebecca C Arend, Amy Jackson-Fisher, Ira A Jacobs, et al.
Pageof 74

Showing results (121-130 of 738) with videos related to

Sort By:
Pageof 74
Gynecologic Oncology|August 20, 2020
Real world experience of poly (ADP-ribose) polymerase inhibitor use in a community oncology practiceCortney M Eakin, Agnes Ewongwo, Lee Pendleton, et al.
Critical Reviews in Oncology/Hematology|November 10, 2012
Antiangiogenic agents as a maintenance strategy for advanced epithelial ovarian cancerBradley J Monk, Heather Dalton, John H Farley, et al.
Gynecologic Oncology|June 23, 2006
Salvage bevacizumab (rhuMAB VEGF)-based therapy after multiple prior cytotoxic regimens in advanced refractory epithelial ovarian cancerBradley J Monk, Ernest Han, Carol A Josephs-Cowan, et al.
International Journal of Gynecological Cancer : Official Journal of the International Gynecological Cancer Society|September 14, 2004
Evaluation of tamoxifen in persistent or recurrent nonsquamous cell carcinoma of the cervix: a Gynecologic Oncology Group studyL R Bigler, J Tate Thigpen, J A Blessing, et al.
Plastic and Reconstructive Surgery|January 1, 1995
Breast reduction for symptomatic macromastia: can objective predictors for operative success be identified?A P Miller, J B Zacher, R B Berggren, et al.
Journal of Lower Genital Tract Disease|April 7, 2007
Is atypical squamous cells that cannot exclude high-grade squamous intraepithelial lesion clinically significant?Michael T McHale, Jessica Souther, John C Elkas, et al.
International Journal of Gynecological Cancer : Official Journal of the International Gynecological Cancer Society|July 13, 2007
Bevacizumab demonstrates activity in advanced refractory fallopian tube carcinomaN Arora, D Tewari, C Cowan, et al.
Clinical Oncology (Royal College of Radiologists (Great Britain))|August 3, 2010
First quinquennial review of intensity-modulated radiotherapy at St Bartholomew's Hospital, LondonD Smith, N MacDougall, J Monk, et al.
Gynecologic Oncology|September 30, 1999
Does human papillomavirus have a role in cancers of the uterine corpus?W R Brewster, B J Monk, R A Burger, et al.
Cancer Biology & Therapy|January 11, 2021
Ovarian cancer: new strategies and emerging targets for the treatment of patients with advanced diseaseRebecca C Arend, Amy Jackson-Fisher, Ira A Jacobs, et al.
Pageof 74